Interstitial lung disease

Professor Athol Wells, Group Leader

 

Main research areas can be subdivided into two intersecting areas: clinical science with careful quantification of disease (with application, equally, to clinical practice and studies of pathogenesis); and genetic studies with identification of associations with disease and severity of outcome in meticulously phenotyped patients.  With respect to achievement, our unit has published papers with major international impact in both areas.

Current major research questions can also be subdivided into clinical scientific and genetic statements of intent.  In clinical science, we are on the verge of achieving major insights into the pathogenesis of a number of diffuse lung diseases by examining disease severity and potentially key pathogenetic factors jointly against observed disease behaviour, as judged by serial lung function tests and mortality.  We are also taking part in a global pharmaceutical initiative to find new therapies for fibrotic lung disease. 

In genetic research, we have identified the complete genetic susceptibility to one form of sarcoidosis and are making major inroads into other subsets. In systemic sclerosis we are making major progress in refining associations against.  In both diseases, we are playing a driving role in constructing major international coalitions.